<DOC>
	<DOCNO>NCT00237536</DOCNO>
	<brief_summary>The purpose trial evaluate dose response relationship lonidamine primary efficacy endpoint , International Prostate Symptom Score ( IPSS ) , subject symptomatic benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Study Efficacy Safety Lonidamine Treatment Symptomatic Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lonidamine</mesh_term>
	<criteria>1 . Capable understanding purpose risk study sign statement inform consent 2 . Male 6580 year age ( 4080 vasectomy ) . Vasectomized men must documentation azoospermia . 3 . Presence LUTS ( low urinary tract symptom ) least 3 month 4 . Prostate volume measure TRUS ( transrectal ultrasound ) &gt; 30 cc 5 . Qmax &lt; 15 mL/sec measure uroflowmetry ( minimum 125 mL must void ) 6 . IPSS ( International Prostate Symptom Score ) &gt; 12 7 . PSA &gt; 1.0 ng/mL 8 . Must ensure consent use medically acceptable method contraception throughout entire study sexual partner childbearing potential 9 . Able comply prescribe treatment protocol evaluation 1 . Prior treatment BPH alpha blocker and/or herbal supplement treatment BPH past 2 week ( alphablockers and/or herbal supplement treatment BPH allow study ) . Prior treatment 5alpha reductase inhibitor allow discontinue least 3 month prior enrollment . 2 . Prior surgery prostate ( except biopsy ; subject eligible enroll one month full recovery prostate biopsy . ) 3 . Current past evidence malignant disease prostate prostatic intraepithelial neoplasia ( For subject PSA 4 10 ng/mL , prostate cancer must rule satisfaction Principal Investigator . Subjects PSA &gt; 10 ng/mL exclude ) . 4 . Active urinary tract infection ( UTI ) 5 . Active cardiac , renal hepatic disease evidence : 1 . Serum creatinine &gt; 1.8 mg/dL 2 . ALT AST &gt; 2.5x upper limit normal 3 . History active myocardial infarction , unstable cardiac arrhythmia , stroke within 6 month prior screen 4 . Uncontrolled congestive heart failure 6 . Uncontrolled diabetes mellitus ( fast blood glucose &gt; 200 mg/dL ) 7 . Use systemic steroid reason ( systemic steroid usage allow study ) . Inhaled and/or topical steroid allow . 8 . Concurrent participation participation investigational drug study within past 30 day prior screen 9 . Concomitant disease condition could interfere conduct study , would opinion Investigator , pose unacceptable risk subject</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged Prostate</keyword>
</DOC>